Therapeutic targeting of the tumor microenvironment.

By J. Joyce. Cancer Cell, 2005

1,449 citations recorded by the source corpus.

Cancer is not a solo performance, but rather an ensemble production. Tumor cells play the leading villains, with a diverse supporting cast of normal cells that can be recruited to aid their malignant progression. The supporting players in the tumor microenvironment include stromal fibroblasts, infiltrating immune cells, the blood and lymphatic vascular networks, and the extracellular matrix (Figure 1). Normal cells can contribute both positive and negative signals to the tumor. They can be co-opted or modified by the cancer cells to produce a variety of growth factors, chemokines, and matrix-degrading enzymes that enhance the proliferation and invasion of the tumor.

Subfields: Cancer Research, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/c8f27ec7356d501eb2d35382d3bc95fe31e89dbb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

In Oncology

Citations in the corpus

Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach (2006, neutral): “Clinical data collected from a wide range of solid tumours underscore these findings given that high densities of leucocytic infiltrations, most notably macrophages, correlate with poor prognosis of the diseases (Chen et al, 2005; Joyce, 2005).”
Modelling breast cancer: one size does not fit all (2007, neutral): “Thus, elucidating the mechanisms that regulate these interactions is critical and may yield new targets within the stromal environment for cancer therap”
3D tumor spheroids as in vitro models to mimic in vivo human solid tumors resistance to therapeutic drugs (2018, background): “…tumor stroma cells targeted therapeutic approaches have been investigated and are currently under evaluation, as reviewed in detail by several authors (Bahrami & Hassanian, 2018; H. Fang & DeClerck, 2013; Joyce, 2005; Mao et al., 2013; Sounni & Noel, 2013; Sun, 2016; J. Zhang & Liu, 2013).”
New horizons in tumor microenvironment biology: challenges and opportunities (2015, neutral): “Introduction Cancer is a systemic disease, and it is not a solo production but rather an ensemble performance [1].”
Matrix metalloproteinases and tumor metastasis (2006, neutral): “These observations appear to clearly implicate MMPs of both tumor and stromal origin in the induction of metastasis [8, 14, 23, 24, 56, 62, 116, 117].”
Clinical relevance of tumour-associated macrophages (2022, background): “Several aspects currently being addressed include: (1) the complexity and diversity of macrophages, and whether distinct macrophage states can be identified; (2) whether and how different macrophage states contribute to disease progression or suppression; (3) the possibility of rational manipulation”
New signals from the invasive front (2006, neutral): “In particular, monocytes and their differentiated/activated derivatives, infiltrating tumour-associated macrophages (TAMs), are found in high numbers in tumour”
Multimodal data fusion for cancer biomarker discovery with deep learning (2023, background): “Furthermore, the cellular composition of the TME dynamically evolves with tumour progression and in response to anticancer treatments 45,46 .”
Tumors as organs: complex tissues that interface with the entire organism (2010, neutral): “Direct targets in the tumor microenvironment that have been or are being tested in clinical trials include the ECM, endothelial 896 Developmental Cell 18, June 15, 2010 ª2010 Elsevier Inc. cells and pericytes, fibroblasts, and innate immune cells (reviewed in Joyce, 2005).”
The tumour microenvironment as a target for chemoprevention (2007, neutral): “Although there are many excellent recent reviews on the tumour microenvironment, and it has recently been proposed as a target for therap”
Microenvironmental regulation of metastasis (2009, neutral): “Although it is probably optimistic to think that all changes can be fully reversed, various strategies have been used to target stromal cells, particularly in the primary tumou”
Targeting Tumor Microenvironment for Cancer Therapy (2019, background): “Considering the role of immune system in cancer, several routes could be used to tackle tumor progression: (1) inhibition of macrophage recruitment into tumor tissues; (2) inhibition of macrophage differentiation into the pro-tumoral phenotype (TAMs); (3) target chronic inflammation or pro-tumorigen”
Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics (2022, background): “Emerging drugs are beginning to take a more comprehensive perspective of the tumor microenvironment (TME) and are revealing complementary techniques to simultaneously restore and enhance immune activity and promote therapeutic synergy.(267,268) Future research of combined therapy should continue to ”